7022 Background: A previous CALGB trial suggested a benefit for carboplatin-paclitaxel
(CP) over P alone in pts with PS 2. Erlotinib (E) has activity in previously treated pts with low …

7011 Background: Tarceva™(erlotinib) is a potent reversible HER1/EGFR tyrosine kinase
inhibitor with single-agent antitumor activity. TRIBUTE was a prospective, placebo-controlled …

7160 Background: The HER1/EGFR inhibitor erlotinib significantly prolongs survival of
patients with previously-treated advanced NSCLC. Methods for selecting patients most likely …

Purpose A multicenter randomized phase II trial to evaluate two treatment strategies in the
first-line management of advanced non–small-cell lung cancer (NSCLC) patients with a …

Purpose Erlotinib is a potent reversible HER1/epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor with single-agent activity in patients with non–small-cell lung cancer …

LBA7523 Background: PF299804, a potent, irreversible inhibitor of human epidermal growth
factor receptor (HER)-1/EGFR,-2, and-4 tyrosine kinases (TK), is active in E-sensitive and …

Purpose This phase II study (S0341) evaluated the efficacy and tolerability of single-agent
erlotinib in unselected chemotherapy-naive patients with advanced non-small cell lung …

7010 Background: Oral erlotinib is a potent HER1/EGFR tyrosine kinase-phosphorylation
inhibitor with single-agent antitumor activity and has shown additive effects when added to …

8031 Background: Concurrent administration of EGFR TKIs and chemotherapy in 1st line
failed to improve survival. Preclinical data suggested potential antagonism due to TKI …

7508 Background: In a placebo-controlled trial, E prolonged survival of unselected aNSCLC
patients (pts) not eligible for further chemotherapy. Two phase II studies suggested that first …